Clinical trial · Interventional
Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression
Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The myeloma microenvironment is the target of many drugs in development, and it is unclear how they can be combined with reference treatments such as lenalidomide. This pilot study consists of an extensive phenotypic characterisation of the impact of lenalidomide combined with dexamethasone on the bone marrow microenvironment of a homogeneous cohort of non-pretreated MM patients. Blood sampling will be systematically performed in a matched fashion to monitor the general effect of lenalidomide on the immune system and to detect possible peripheral markers. This study will provide rational guidance for future combination therapies with lenalidomide.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood and bone marrow sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients
- description
- All patients will have a extra blood sampling before first cycle of treatment and after one cycle. They also have an extra bone marrow sampling after the first cycle of treatment
- interventionNames
- Other: Blood and bone marrow sampling
Primary outcomes (1)
- measure
- Rate of HLA-DR on medullary T-lymphocytes
- timeFrame
- 1 month
- description
- Changed expression of HLA-DR on medullary T-lymphocytes after exposure to lenalidomide-dexamethasone.
Secondary outcomes (1)
- measure
- Activation status of biological markers
- timeFrame
- 1 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with newly diagnosed multiple myeloma; * Patient not eligible for intensive treatment; * Patient for whom first-line treatment with Lenalidomide-Dexamethasone will be initiated; * Patient accepting the performance of an additional myelogram at the end of the 1st treatment cycle. * Patient aged 18 years or older; * Patient who has given free, informed and written consent; * Patient affiliated to a social security scheme * For women of childbearing age, use of effective contraception Exclusion Criteria: * Patient with relapsed multiple myeloma; * Patient eligible for intensive treatment; * Patient for whom chemotherapy involves treatment other than Lenalidomide-Dexamethasone; * Patient with a contraindication to lenalidomide treatment * Pregnant or breastfeeding woman; * Person subject to legal protection (safeguard of justice, curatorship,guardianship) or person deprived of liberty.
References
Publications (0)
Data not yet available